tetano
Editor, Senior Moderator
Am J Clin Pathol
. 2021 Jan 5;aqaa268.
doi: 10.1093/ajcp/aqaa268. Online ahead of print.
Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma
Joanna Balcerek[SUP] 1 [/SUP], Evelin Trejo[SUP] 2 [/SUP], Kendall Levine[SUP] 2 [/SUP], Paul Couey[SUP] 2 [/SUP], Zoe V Kornberg[SUP] 3 [/SUP], Camille Rogine[SUP] 3 [/SUP], Charlotte Young[SUP] 3 [/SUP], P Jonathan Li[SUP] 3 [/SUP], Brian R Shy[SUP] 1 [/SUP], Jordan E Taylor[SUP] 1 [/SUP], Sara Bakhtary[SUP] 1 [/SUP], Terence Friedlander[SUP] 2 [/SUP], Kara L Lynch[SUP] 1 [/SUP], Caryn Bern[SUP] 4 [/SUP], Jonathan H Esensten[SUP] 1 [/SUP]
Affiliations
Abstract
Objectives: Serologic testing for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in potential donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) may not be performed until after blood donation. A hospital-based recruitment program for CCP may be an efficient way to identify potential donors prospectively.
Methods: Patients who recovered from known or suspected COVID-19 were identified and recruited through medical record searches and public appeals in March and April 2020. Participants were screened with a modified donor history questionnaire and, if eligible, were asked for consent and tested for SARS-CoV-2 antibodies (IgG and IgM). Participants positive for SARS-CoV-2 IgG were referred for CCP collection.
Results: Of 179 patients screened, 128 completed serologic testing and 89 were referred for CCP donation. IgG antibodies to SARS-CoV-2 were detected in 23 of 51 participants with suspected COVID-19 and 66 of 77 participants with self-reported COVID-19 confirmed by polymerase chain reaction (PCR). The anti-SARS-CoV-2 IgG level met the US Food and Drug Administration criteria for "high-titer" CCP in 39% of participants confirmed by PCR, as measured by the Ortho VITROS IgG assay. A wide range of SARS-CoV-2 IgG levels were observed.
Conclusions: A hospital-based CCP donor recruitment program can prospectively identify potential CCP donors. Variability in SARS-CoV-2 IgG levels has implications for the selection of CCP units for transfusion.
Keywords: COVID-19; Convalescent plasma; Coronavirus; Donor recruitment; SARS-CoV-2.
. 2021 Jan 5;aqaa268.
doi: 10.1093/ajcp/aqaa268. Online ahead of print.
Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma
Joanna Balcerek[SUP] 1 [/SUP], Evelin Trejo[SUP] 2 [/SUP], Kendall Levine[SUP] 2 [/SUP], Paul Couey[SUP] 2 [/SUP], Zoe V Kornberg[SUP] 3 [/SUP], Camille Rogine[SUP] 3 [/SUP], Charlotte Young[SUP] 3 [/SUP], P Jonathan Li[SUP] 3 [/SUP], Brian R Shy[SUP] 1 [/SUP], Jordan E Taylor[SUP] 1 [/SUP], Sara Bakhtary[SUP] 1 [/SUP], Terence Friedlander[SUP] 2 [/SUP], Kara L Lynch[SUP] 1 [/SUP], Caryn Bern[SUP] 4 [/SUP], Jonathan H Esensten[SUP] 1 [/SUP]
Affiliations
- PMID: 33399201
- DOI: 10.1093/ajcp/aqaa268
Abstract
Objectives: Serologic testing for antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in potential donors of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) may not be performed until after blood donation. A hospital-based recruitment program for CCP may be an efficient way to identify potential donors prospectively.
Methods: Patients who recovered from known or suspected COVID-19 were identified and recruited through medical record searches and public appeals in March and April 2020. Participants were screened with a modified donor history questionnaire and, if eligible, were asked for consent and tested for SARS-CoV-2 antibodies (IgG and IgM). Participants positive for SARS-CoV-2 IgG were referred for CCP collection.
Results: Of 179 patients screened, 128 completed serologic testing and 89 were referred for CCP donation. IgG antibodies to SARS-CoV-2 were detected in 23 of 51 participants with suspected COVID-19 and 66 of 77 participants with self-reported COVID-19 confirmed by polymerase chain reaction (PCR). The anti-SARS-CoV-2 IgG level met the US Food and Drug Administration criteria for "high-titer" CCP in 39% of participants confirmed by PCR, as measured by the Ortho VITROS IgG assay. A wide range of SARS-CoV-2 IgG levels were observed.
Conclusions: A hospital-based CCP donor recruitment program can prospectively identify potential CCP donors. Variability in SARS-CoV-2 IgG levels has implications for the selection of CCP units for transfusion.
Keywords: COVID-19; Convalescent plasma; Coronavirus; Donor recruitment; SARS-CoV-2.